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OBJECTIVES We sought to determine whether seropositivity to Helicobacter pylori, Chlamydia pneumoniae,
and cytomegalovirus (CMV) is an independent predictor of incident cardiovascular disease.
BACKGROUND Recent reports have suggested that infections may contribute to risk of cardiovascular disease.
However, prospective studies of these associations in a free-living population are lacking.
METHODS We measured serum H. pylori IgG, C. pneumoniae IgG and IgA, and CMV IgG levels in
Framingham Heart Study cohort participants. Blood samples were drawn during the 16th
biennial examination cycle (1979 to 1982) from 1,187 participants free of cardiovascular
disease (mean age 69 years) and stored at 20°C. A pooled primary end point of myocardial
infarction, atherothrombotic stroke, and coronary heart disease deaths was studied in relation
to serology. Using a Cox model, hazard ratios (HR) and 95% confidence intervals (CI) were
calculated, adjusting for age, gender, and established risk factors.
RESULTS Seropositivity to H. pylori IgG, C. pneumoniae IgG, C. pneumoniae IgA, and CMV IgG was
60%, 45%, 11%, and 69%, respectively. During 10 years of follow-up, incident cardiovascular
disease occurred in 199 participants (16.8%). In age- and gender-adjusted models, H. pylori
IgG (HR 1.09, 95% CI 0.81 to 1.46), C. pneumoniae IgG (HR 0.91, 95% CI 0.68 to 1.20),
C. pneumoniae IgA (HR 0.65, 95% CI 0.39 to 1.07), and CMV IgG (HR 0.84, 95% CI 0.62
to 1.12) were not associated with incident cardiovascular disease. These associations were
further attenuated after adjustment for risk factors including body mass index, total and
high-density lipoprotein cholesterol, diabetes mellitus, smoking, and hypertension. These
estimates did not change for the individual components of cardiovascular disease, and
seropositivity to more than one organism did not alter these risk estimates substantially.
CONCLUSIONS In this elderly cohort, chronic H. pylori, C. pneumoniae, and CMV infections, as evidenced by
seropositivity, were not associated with increased risk for cardiovascular disease. Additional
studies are needed to determine the relations of chronic infections to cardiovascular disease
risk in younger persons. (J Am Coll Cardiol 2002;40:1408–13) © 2002 by the American
College of Cardiology Foundation
Systemic response to chronic infections may play an impor-
tant role in the pathogenesis of atherosclerosis (1). Recently,
there has been a resurgence of interest in examining the role
of chronic bacterial and viral infections and accompanying
inflammation in the pathogenesis of atherosclerotic cardio-
vascular diseases (2,3). Several studies have reported an
increased risk of myocardial infarction (MI), coronary
death, and stroke in association with Helicobacter pylori,
Chlamydia pneumoniae, and cytomegalovirus (CMV) infec-
tions (2–4), but only few reports (4–6) have measured
antibodies to all three agents in the same population.
Reports of such associations have raised the possibility that
anti-infective treatments might be able to prevent cardio-
vascular disease (7,8). However, most of the reported
positive associations emanate from case-control studies or
studies conducted in hospitals, and only a few have reported
prospective follow-up for co-infection with more than one
organism in a community-based sample (2–4).
Many established risk factors might influence the devel-
opment of cardiovascular disease. It is therefore important
to account for these potential confounders. Also, previously
published studies of infection and cardiovascular disease
have generally been prone to biases and have lacked ade-
quate sample sizes (2–4). The Framingham Heart Study
provides an opportunity to examine the role of chronic
infections in the pathogenesis of cardiovascular disease.
To this end, we have examined the association of
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seropositivity to H. pylori, C. pneumoniae, and CMV with
the risk of development of cardiovascular disease in the
original Framingham Heart Study cohort. This is a
carefully described population in which standard risk
factors are routinely measured and ascertainment for end
points is extensive.
METHODS
The Framingham Heart Study, which began in 1948 with
5,209 participants aged 28 to 62 years, has followed subjects
at regular intervals as part of a prospective epidemiologic
investigation of cardiovascular disease. Enrollment criteria
and study design have been published previously (9). Bien-
nial follow-up visits included a medical history, physical
examination, blood pressure measurements, and laboratory
tests. Participants who were free of cardiovascular disease at
the 16th examination (1979 to 1982) and who had a stored
blood sample were eligible for the present investigation.
Methodology for assessing risk factors has been published
previously (9,10). Risk factors including age, gender, ciga-
rette smoking, total and high-density lipoprotein (HDL)
cholesterol, and blood pressure were assessed at the baseline
examination. Body mass index (kg/m2) was used as a
measure of obesity. Participants were categorized as smokers
if they currently smoked cigarettes regularly or if they had
quit within a year before the baseline examination. Diabetes
mellitus was defined on the basis of a fasting blood glucose
level greater than 140 mg/dl (7.77 mmol/l), two random
nonfasting levels greater than 200 mg/dl (11.10 mmol/l), or
the use of insulin or an oral hypoglycemic agent.
The primary end point was the occurrence of cardiovas-
cular disease, which encompassed three outcomes: incident
MI, death from coronary heart disease, and fatal or nonfatal
atherothrombotic stroke. Criteria for MI have been de-
scribed previously (10). At each clinic examination a history
of interim hospitalizations and symptoms of heart disease
were recorded. Outside medical records of participants who
did not attend an examination were obtained and evaluated
for interim MI. All suspected interim events were evaluated
by a panel of three physicians who reviewed relevant
Framingham Heart Study clinic notes, hospitalization
records, and pathology reports. Myocardial infarction was
diagnosed when at least two of the following criteria were
fulfilled: 1) symptoms consistent with MI; 2) diagnostic
electrocardiographic changes of MI; and 3) diagnostic
elevation of biomarkers. Death was attributed to the coro-
nary heart disease if there was evidence that coronary heart
disease resulted in death and a noncoronary heart disease
cause of death was not suspected. Additional information
was obtained from records supplied by the hospital or
private physician, pathologist, medical examiner, or family
(9). The criteria employed for the diagnosis of stroke have
been published previously (10). The stroke entity included
atherothrombotic brain infarction. Minimum criteria for a
stroke consisted of a focal neurological deficit of abrupt
onset lasting more than 24 h without other explanation.
Subjects were often examined at the time of hospitalization
and subsequently in the Framingham Heart Study clinic by
a qualified neurologist assigned to the study. Each new case
was verified by a review panel of physicians, including a
neurologist (10).
Laboratory protocol. Blood samples were collected from
the original cohort (n  1,503) at the baseline examination.
Serum was frozen in glass vials and stored at 20°C.
Specimens were thawed and aliquotted into cryogenic vials
beginning in the summer of 1997. One aliquot was shipped
on dry ice by courier to Medical Reference Laboratory
(Cypress, California). Laboratory personnel were blinded to
the clinical status of the study participants. Commercially
available IgG antibody tests for H. pylori, C. pneumoniae,
and CMV were conducted according to the manufacturer’s
instructions. Blinded duplicate specimens were included
(2%) to assess the reproducibility of the laboratory tests, as
measured by between-subject variance as a percentage of
total variance. Reproducibility estimates were 98% for H.
pylori and CMV, 69% for C. pneumoniae IgG, and 41% for
C. pneumoniae IgA.
HELICOBACTER PYLORI IgG. Sera were diluted in sample
buffer, and 0.1 ml was added to individual microtiter wells
(Enteric Products International kit). After 20 min at room
temperature, plates were washed three times, and 0.1 ml of
horseradish peroxidase–conjugated goat anti-human IgG
was added. After 20 min at room temperature the plates
were washed. Thrombo broth was added, and after 10 min,
1N sulfuric acid was added to stop the reaction. Absorbance
was read at 450 nm. Absorbance values were converted to
ELISA values using a 3-point standard curve. As recom-
mended by the manufacturer, an ELISA value 2.2 was
considered positive.
CHLAMYDIA PNEUMONIAE IgG AND IgA. Slides containing C.
pneumoniae elementary bodies attached to the glass were
used. There were 12 wells per slide. Sera were diluted 1:16,
1:64, and 1:256 in sample buffer. For IgG measurements,
0.025 ml of each dilution was added to slide wells. After 1 h
at 37°C, the slides were washed and dried and then treated
with FITC-conjugated goat anti-human IgG or FITC-
conjugated goat anti-human IgA. After 30 min at 37°C,
slides were washed and dried as before. Glycerol mounting
sodium was added, along with a coverslip. Slides were
examined using a fluorescent microscope at 400. The
presence of antibody was indicated by fluorescence of
elementary bodies. If the IgA was positive then all three
Abbreviations and Acronyms
CI  confidence interval
CMV  cytomegalovirus
HDL  high-density lipoprotein
HR  hazard ratio
MI  myocardial infarction
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dilutions were tested to determine the titer. For IgG, titers
of 1:128 or greater and for IgA a titer of 1:32 or higher were
considered positive as per laboratory protocol.
CYTOMEGALOVIRUS IgG. Sera were diluted 1:21 in sample
buffer, and 0.1 ml was added to individual microtiter wells
(Zeus Scientific kit). After 20 min at room temperature,
plates were washed three times, and 0.1 ml of horseradish
peroxidase-conjugated goat anti-human IgG was added.
After 20 min at room temperature the plates were washed as
before, and 1N sulfuric acid was added to stop the reaction.
Absorbance was read at 450 nm. An index value was
calculated by dividing the patient absorbance value by a
cutoff absorbance value (determined by multiplying the low
positive control absorbance value by a kit-specific conver-
sion factor). Index values3.52 were considered positive, as
recommended by the manufacturer.
Data analysis. Prevalence of positive serology for H. pylori,
C. pneumoniae, and CMV antibodies as a function of age,
gender, and other demographic features was determined.
The association of positive serology with incident cardio-
vascular events was examined in participants free of cardio-
vascular disease at the baseline examination. Cox propor-
tional hazards regression models were used to analyze time
to end points (11). Hazard ratios (HR) and 95% confidence
intervals (95% CI) were calculated after adjusting for age
and gender as well as body mass index, total and HDL
cholesterol, diabetes mellitus, smoking, and hypertension.
The sample size was sufficient to detect an HR of 1.5 or
larger with 80% power at the 5% level of significance, for
each of the infective agents. Secondary analyses were carried
out for incident MI, coronary heart disease death, and
stroke.
RESULTS
The mean age of study participants was 69 years at the
baseline examination. Table 1 shows the demographics and
clinical characteristics of the study sample. Seropositivity to
H. pylori, C. pneumoniae IgG and IgA, and CMV was 60%,
45%, 11%, and 69%, respectively. Seropositivity to H. pylori
and C. pneumoniae was higher in men, whereas seropositiv-
ity to CMV was higher in women (Table 2). Seropositivity
to CMV increased with age in men and women (p 
0.006), whereas no such pattern was observed for H. pylori
or C. pneumoniae (Table 3).
During an average of 10 years (maximum 13 years) of
follow-up, 199 (16.8%) of those free of cardiovascular
disease at baseline developed an incident cardiovascular
event. Table 4 shows the association of seropositivity to each
of the agents with new-onset cardiovascular disease. None
of the organisms was associated with incident cardiovascular
disease in age- and gender-adjusted models, or after adjust-
ment for other risk factors. These estimates did not change
for the individual components of cardiovascular disease, and
secondary analyses for MI, coronary heart disease death, and
stroke revealed no significant association of seropositivity to
the organisms with these end points (data not shown).
The presence of co-infections did not impart a greater
risk for development of cardiovascular disease, and seropos-
itivity to two or more agents was not associated with
incident events (Table 5). Risk estimates did not change
substantially when the definition of seropositivity was
changed around the predefined levels for each infection
(Table 6).
DISCUSSION
Our study revealed no significant association between H.
pylori, C. pneumoniae, and CMV infection and incidence of
cardiovascular disease. Our results do not support a role of
CMV in promoting the risk of cardiovascular disease
(HR  0.90). Age- and gender-adjusted analyses revealed
no association of H. pylori seropositivity with incident
cardiovascular disease (HR  1.09), and it was further
attenuated after adjustment for confounders (HR  1.02).
Our analyses also failed to reveal any association of C.
pneumoniae IgG (HR  0.86) and C. pneumoniae IgA
(HR  0.77) with incident cardiovascular events.
Several studies have reported associations between
chronic infection with H. pylori, C. pneumoniae, or CMV
and risk for coronary heart disease (2,3). It is unclear
whether infection with any of these agents is really associ-
ated with coronary heart disease because some of these
studies were prone to selection biases, limited by small
Table 1. Clinical Characteristics of the Study Population
All Subjects
(n  1,187)
Age (yrs) 69  7
Body mass index (kg/m2) 26.7  4.4
Men (%) 38
Smokers (%) 22
Hypertension (%) 61
Diabetes (%) 8
Total cholesterol (mg/dl) 229  40
HDL cholesterol (mg/dl) 51  15
Data are mean  SD, or percent.
HDL  high-density lipoprotein.
Table 2. Prevalence of Seropositivity by Gender
Men (%) Women (%) p Value
Helicobacter pylori IgG (2.2) 66.5 56.4  0.001
Chlamydia pneumoniae IgG (1:128) 58.1 36.7  0.001
Chlamydia pneumoniae IgA (1:32) 16.7 8.2  0.001
Cytomegalovirus IgG (3.52) 62.5 72.8  0.001
Table 3. Prevalence of Cytomegalovirus Seropositivity by Age*
and Gender† Group
<70 Years (%) 70–79 Years (%) >80 Years (%)
Men 59.3 65.9 73.8
Women 69.6 74.9 82.3
*Age group differences: chi-square  10.18, 2 df, p  0.006, accounting for gender
difference. †Gender difference: chi-square  12.39, 1 df, p  0.001, accounting for
age group differences.
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sample sizes, did not adequately account for possible con-
founders, and mostly examined only one infectious agent. It
is likely that chance, or publication bias (2–5) or both, may
explain the positive associations reported in smaller studies
but not in larger population-based studies (2,5,12,13). More
recent prospective cohort studies have also shown similar
negative or less extreme results (4).
Comparison with previous studies. This population-
based, prospective study of a large cohort was adjusted for
established cardiovascular disease risk factors. It confirmed
results reported by larger studies. For H. pylori, the adjusted
HR of 1.02 is similar to previous reports in the elderly (14),
in participants of the ARIC study (15), in two British
studies (12,16), and a review of prospective reports (2).
Thus, although previous cross-sectional studies have sug-
gested an association and despite potential pathogenetic
mechanisms (17–19), our study and more recent reports do
not support a strong association of H. pylori with risk of
cardiovascular disease. Because of confounding by socioeco-
nomic status, associations between H. pylori and coronary
heart disease are difficult to interpret even in population-
based studies (20). However, our study, which comprised a
large, relatively homogeneous sample, confirms previous
observations of a lack of association of this organism with
cardiovascular disease (5,12,14–16).
Several studies have previously reported an association of
C. pneumoniae infection with risk for coronary heart disease
(21–25). Most of these studies measured IgG, but only
three prospective studies measured IgA (26–28). Larger
population-based studies have not supported an association
of C. pneumoniae infection with cardiovascular disease (5,29)
or reported only a weakly positive association (28). The
relative risk (RR) estimates of the present study do not
suggest an association of C. pneumoniae IgG (HR 0.86; 95%
CI 0.64 to 1.16) or C. pneumoniae IgA (HR 0.77; 95% CI
0.47 to 1.28) with cardiovascular disease. Therefore, the
hypothesis that chronic infection or past C. pneumoniae
exposure is associated with cardiovascular disease risk is not
supported by our study. It is to be noted that evidences of
chronic infection such as the presence of C. pneumoniae
within the atherosclerotic plaque and its detection within
peripheral blood mononuclear cells do not correlate well
with serology (2). Therefore, whether or not serologic titers
to C. pneumoniae correlate with chronic infection and
whether the absence of seropositivity to C. pneumoniae
correlates with the absence of previous exposure remain to
be demonstrated.
Earlier studies have mostly reported association of CMV
infection with coronary atherosclerosis in transplanted
hearts, following coronary angioplasty, or in carotid arteries
(2,3). In a previous investigation from the Framingham
Heart Study, no association between clinically apparent
herpes virus infection and coronary heart disease was doc-
umented (30). Recent prospective studies have also failed to
demonstrate an association of CMV infection with risk of
cardiovascular disease (5,6,13,31). Our study confirms these
observations from population-based studies (5,6,13,31), and
it does not indicate a strong association between CMV
infection and risk of cardiovascular disease. Although it has
been suggested that co-infection with more than one
organism may cause greater inflammatory burden, we were
unable to detect increased risk of cardiovascular disease in
association with infection with more than one agent (Table 5).
Study implications. This report, in context with the pre-
viously reported larger studies, shows the pathogens de-
scribed in this study are unlikely to be strong predictors of
risk of cardiovascular disease. Because these infections are
Table 4. Seropositivity and Risk of Cardiovascular Disease
Hazard Ratio
(95% Confidence Intervals)
Age and gender adjusted
Helicobacter pylori IgG (2.2) 1.09 (0.81–1.46)
Chlamydia pneumoniae IgG (1:128) 0.91 (0.68–1.20)
Chlamydia pneumoniae IgA (1:32) 0.65 (0.39–1.07)
Cytomegalovirus IgG (3.52) 0.84 (0.62–1.12)
Age, gender, and risk factor adjusted*
Helicobacter pylori IgG (2.2) 1.02 (0.75–1.40)
Chlamydia pneumoniae IgG (1:128) 0.86 (0.64–1.16)
Chlamydia pneumoniae IgA (1:32) 0.77 (0.47–1.28)
Cytomegalovirus IgG (3.52) 0.90 (0.66–1.24)
*Adjusted for age, gender, body mass index, total and high-density lipoprotein
cholesterol, diabetes mellitus, smoking, and hypertension.
Table 5. Co-Infection and Risk of Cardiovascular Disease
*Hazard Ratio
(95% Confidence Intervals)
Seropositivity to any one organism 0.88 (0.50–1.56)
Seropositivity to any two organisms 0.78 (0.45–1.37)
Seropositivity to any three organisms 0.77 (0.44–1.35)
*Adjusted for age, gender, body mass index, total and high-density lipoprotein
cholesterol, diabetes mellitus, smoking, and hypertension.
Table 6. Prevalence of Seropositivity and Risk of Cardiovascular
Disease With Variable Threshold Values
Prevalence
(%)
Hazard Ratio
(95% Confidence
Intervals)*
Helicobacter pylori IgG (1.8) 63.6 1.17 (0.84–1.62)
Helicobacter pylori IgG (2.2) 60.2 1.02 (0.75–1.40)
Helicobacter pylori IgG (3.7) 50.0 1.06 (0.78–1.42)
Helicobacter pylori IgG (6.0) 24.7 1.05 (0.76–1.45)
Helicobacter pylori IgG (6.5) 19.9 1.19 (0.85–1.66)
Chlamydia pneumoniae IgG (1:32) 65.8 0.96 (0.70–1.32)
Chlamydia pneumoniae IgG (1:64) 59.9 0.95 (0.70–1.30)
Chlamydia pneumoniae IgG (1:128) 44.9 0.86 (0.64–1.16)
Chlamydia pneumoniae IgG (1:256) 32.9 0.83 (0.60–1.13)
Chlamydia pneumoniae IgA (1:16) 22.7 0.85 (0.59–1.22)
Chlamydia pneumoniae IgA (1:32) 11.5 0.77 (0.47–1.28)
Chlamydia pneumoniae IgA (1:64) 9.9 0.65 (0.36–1.17)
Cytomegalovirus IgG (3.04) 75.3 0.80 (0.58–1.11)
Cytomegalovirus IgG (3.52) 68.9 0.90 (0.66–1.24)
Cytomegalovirus IgG (4.38) 50.5 0.79 (0.59–1.07)
Cytomegalovirus IgG (5.01) 26.7 0.78 (0.55–1.12)
Cytomegalovirus IgG (5.50) 11.4 0.87 (0.53–1.43)
*Adjusted for age, gender, body mass index, total and high-density lipoprotein
cholesterol, diabetes mellitus, smoking, and hypertension.
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potentially treatable, a reliable assessment of even a small
increase in risk would be epidemiologically significant,
particularly if interventions might be able to prevent some of
the sequelae (4,5). Additional studies are therefore needed
to explore the relation of chronic infections with cardiovas-
cular disease risk in younger persons. Such studies may be
particularly informative in association with virulent strains,
such as Cag A-bearing H. pylori (32) and in susceptible
subjects due to genetic predisposition (33). Though some
studies have suggested a beneficial role of a short course of
antibiotics to treat patients with acute coronary syndromes
(7,8,34), our study does not support eradication of H. pylori,
C. pneumoniae, and CMV infection to prevent cardiovascu-
lar disease. This is in agreement with recently reported large
antibiotic trials that failed to show benefit in postmyocardial
infarction or unstable angina patients with elevated C.
pneumoniae titers (35). At present, the evidence is insuffi-
cient to designate infections as a causal risk factor for
cardiovascular disease.
Study strengths and limitations. The Framingham Heart
Study is a large population-based sample in which risk
factors are routinely assessed and the follow-up is extensive.
The study sample comprises both men and women, thus
providing a cohort inherently suitable for examining the
association of chronic infections with cardiovascular disease
(36). Our study sample was overwhelmingly Caucasian;
thus, our findings may not apply to other racial and ethnic
groups in whom the prevalence of traditional risk factors
and chronic infections may be higher. However, the prev-
alence of infections and the risk estimates in the present
study were similar to the results of other population-based
studies that examined associations of chronic infections with
risk of cardiovascular disease (5,13,29). To our knowledge
this is first report that has prospectively examined the
association of seropositivity to more than one agent with
cardiovascular disease in the elderly. The mean age of the
participants was 69 years at the baseline examination, and it
is possible that those most susceptible to atherosclerosis in
response to chronic infection with these organisms may
have been missed. Although it is certainly desirable to repeat
this study in a younger cohort, our observations are in
conformity with population-based studies that have failed to
show strong associations of these infections with cardiovas-
cular disease (29,31,37). Further, this study may be limited
by regression-dilution bias (2) and was not designed to
examine histological or DNA evidence of infection with the
organisms studied, accompanying systemic inflammatory
response and risk of cardiovascular disease.
SUMMARY
In this elderly cohort, chronic H. pylori, C. pneumoniae, and
CMV infections, as evidenced by seropositivity, were not
associated with increased risk for cardiovascular disease.
Additional studies are needed to determine the relation of
chronic infections to cardiovascular disease risk in younger
persons.
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